Medtech
EyeOP1 is an high-intensity focused ultrasound device that is the first non-invasive treatment for glaucoma in China.
A little more than one year after securing $130M in financing, molecular technology company Zymergen has expanded beyond the Golden State to the Emerald City, Seattle.
The company has been especially active in diabetes management with collaboration partners that include medical device giant Medtronic and DexCom.
The FDA has also received 228 reports of EpiPen failures and at least 35 people were hospitalized as a result of those failures.
Cancer treatment is moving rapidly toward personalized medicine and precision medicine thanks to genetic insight.
The company secured a deal to equip Rigshospitalet and Herlev Hospital with modern treatment systems over the next few years.
Osiris has settled a case of accounting fraud with the U.S. SEC, but four former company execs will face charges for the alleged financial misreporting.
The company plans to invest nearly $10 million over five years to establish operations in Indiana.
Here are four players that have the right combination of elements to post an earnings beat this quarter.
Shares of Coloplast are down more than 11 percent this morning after the company presented a new long-term financial guidance that includes a decision to give up on improving its EBIT annually.
PRESS RELEASES